AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03173820 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Conventional
Description: Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
Study NCT02710253 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT02710253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02710253 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT00860600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: 500mg/vial, iv infusion, 3 \~ 5 times/week, 2.5 \~ 3.5 hr/time
Study NCT04194554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: given PO per dose escalation schedule
Study NCT04194554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 22.5 mg q3 month
Study NCT04194554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg daily
Study NCT03260101 — intervention group
Intervention type: OTHER
Intervention: non intervational
Description: Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
Study NCT04194554 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: 5-6 fraction SBRT (total dose: 37.5-40 Gy)
Study NCT04141644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
Study NCT04124068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLO Brilliant Teeth Whitening Device
Description: Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
Study NCT04124068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLO Lit Teeth Whitening Device
Description: Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
Study NCT04124068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLO Science Professional Teeth Whitening Device
Description: Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
Study NCT05996757 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet clothing removal
Description: The participants in the intervention group will have their clothing removed prior to insulation.
Study NCT03795740 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 3-D CT scanning
Description: For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
Study NCT03795740 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3-D CT scanning
Description: For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
Study NCT04141644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
Study NCT02523027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (List No S691/Z0)
Description: (List No S691/Z0)
Study NCT02523027 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Description: (List No- P968/Z0)
Study NCT02523027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counselling
Description: Regular dietary counseling conducted by a trained hospital dietitian.
Study NCT00968500 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires/Interviews
Description: Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer.
Study NCT02154230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)
Description: During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature.
Study NCT02154230 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tap water
Description: During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
Study NCT03881358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ortho-k lenses and thinner spectacles
Description: Conventinally designed (Emerald) ortho-k lenses (target for -4.00D) and thinner specs during day time
Study NCT03881358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: newly designed ortho-k lenses
Description: Newly designed (Topaz) ortho-k lenses for high myopia (target for full correction)
Study NCT06356272 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT05876910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Production Tasks
Description: View visual cues and undergo speech production for 30 minutes. Electrical stimulation of speech related brain regions in the middle of speech production.
Study NCT00727584 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients undergo external beam radiotherapy
Study NCT00727584 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients undergo external beam radiotherapy
Study NCT04034121 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DESolve Cx drug eluting coronary scaffold system
Description: percutaneous coronary intervention
Study NCT02473120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Determination of ESR1 mutations
Description: Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
Study NCT04056104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SpO2 and PIx Measurement
Description: Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
Study NCT02823496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Lotion , BAY 987521
Description: 50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
Study NCT02823496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study NCT05577780 — intervention group
Intervention type: PROCEDURE
Intervention: internal fixation
Description: Patients with femoral neck fractures are treated with pinning or hip arthroplasty, depending on the age of the patient and the presence and degree of displacement
Study NCT01396109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System
Description: Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA\* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
Study NCT02647242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto rehabilitation program of gait with Beat Health device.
Description: The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
Study NCT01396109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh
Description: Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
Study NCT01382810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altaire Gel forming solution
Description: Three times a day for two months
Study NCT01382810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Tears
Description: Three times a day for two months
Study NCT02793609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention is to let patient to go home.
Description: Intervention is to let patient to go home.
Study NCT02793609 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention is to observe women in the ward.
Description: Intervention is to observe women in the ward.
Study NCT02396056 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: BioMend Extend
Description: Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
Study NCT02396056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified BioMend Extend
Description: Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
Study NCT00543725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278
Description: 25 mg tablet once daily for 96 weeks
Study NCT00543725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: 600 mg tablet once daily for 96 weeks
Study NCT01093196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan, Prednisone, Lenalidomide
Description: Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period \[different doses according to the age of patients (65-75 or >75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
Study NCT01093196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Prednisone, Lenalidomide
Description: Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period \[day 21 to 28\]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
Study NCT01093196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide, dexamethasone
Description: Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
Study NCT02377531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early glucose screen group
Description: Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
Study NCT02377531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard glucose screen group
Description: Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
Study NCT02071511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation of ventricular arrhythmias
Description: control group: Ablation of ventricular arrhythmias
Study NCT02071511 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ablation of ventricular arrhythmias + renal denervation
Description: Intervention group: Ablation of ventricular arrhythmias + renal denervation
Study NCT01696565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG2
Description: Injectable
Study NCT04379986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senbiosys
Description: The patients will undergo blood pressure estimation as per clinical routine and will simultaneously wear the device.
Study NCT01027286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitagel
Description: Vitagel applied just prior to closure during primary total knee arthroplasty
Study NCT04322656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lipiflow treatment
Description: Patients will be treated on one eye with Lipiflow
Study NCT03942822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milled chia seeds
Description: 8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia
Study NCT04054661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SD Biosensor STANDARD G6PD Test
Description: The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
Study NCT04054661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pointe Scientific Test Kit
Description: The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
Study NCT01613534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
Study NCT01613534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Argon plasma coagulation treatment followed by placebo administration for four weeks
Study NCT01470937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: acarbose 100 mg PO once daily
Study NCT01470937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: acarbose placebo
Study NCT01751893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henna
Description: natural henna in the form of paste
Study NCT01751893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04744792 — intervention group
Intervention type: OTHER
Intervention: Short Form - 36
Description: Medical outcomes: 36-item short form health survey (SF-36)~The SF-36 was used as a measure of health-related QoL because it is an internationally recognized global measure. It comprises 36 items that measure perceived health on eight scales (i.e., physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role, and mental health) with higher scores (range 0-100) reflecting better perceived health. Additionally, two summary scores can be obtained: the physical component summary score (PCS) and the mental component summary score (MCS).~In addition, this tool has been validated in Turkish patients
Study NCT01869829 — intervention group
Intervention type: DRUG
Intervention: Observational antifungal therapy
Description: Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care.
Study NCT02472548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-RSV(A)
Description: Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
Study NCT00431288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet high in fruits, vegetables, and dairy
Study NCT00431288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine nutrition care
Study NCT01790932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT03027102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNT cells
Description: DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
Study NCT04054661 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HemoCue System
Description: The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
Study NCT03985709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic product
Description: Probiotic (Lactobacillus casei) once daily taken by 3 months.
Study NCT04517994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Treatment
Description: See arm description.
Study NCT04517994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Treatment
Description: See arm description.
Study NCT02228811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2701 tablet
Study NCT03243656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: An oral thrombopoietin receptor agonist
Study NCT02303769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCL 0.4mg
Description: Tamsulosin HCL 0.4mg once a day
Study NCT02303769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin HCL 0.2mg
Description: Tamsulosin HCL 0.2mg once a day
Study NCT04744792 — intervention group
Intervention type: OTHER
Intervention: WHODAS-II
Description: The World Health Organization disability assessment schedule II (WHODAS-II)~The WHODAS-II is an instrument developed by the World Health Organization to assess behavioral limitations and restrictions regarding participation in specific activity domains experienced by an individual independent of their medical diagnosis. The conceptual frame of reference of this instrument is the International Classification of Functioning, Disability, and Health (ICF). Specifically, the instrument is a 36-item, generic, multidimensional questionnaire designed to evaluate the functioning of the individual in six activity domains (i.e., understanding and communicating, getting around, self-care, getting along with people, life activities, and participation in society). This questionnaire has been validated in Turkish patients.